









Markets
/
Stocks
/
nasdaq-halo
/

Halozyme Therapeutics Inc

HALO

63.240USD

+1.200+1.93%

Close 03/25, 16:00（ET）Quotes delayed by 15 min

7.79BMarket Cap

23.92P/E TTM



Halozyme Therapeutics Inc

63.240

+1.200+1.93%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Halozyme Therapeutics Inc

Currency: USD Updated: 2026-03-25

Key Insights

Halozyme Therapeutics Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 36 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 84.50.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Halozyme Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

36 / 157

Overall Ranking

113 / 4547

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Halozyme Therapeutics Inc Highlights

StrengthsRisks

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 68.42% year-on-year.

Overvalued

The company’s latest PE is 23.92, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 124.73M shares, decreasing 2.79% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 1.10K shares of this stock.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

84.500

Target Price

+34.43%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-25

The current financial score of Halozyme Therapeutics Inc is 7.74, ranking 90 out of 157 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 451.77M, representing a year-over-year increase of 51.60%, while its net profit experienced a year-over-year increase of 203.34%.

Score

Industry at a Glance

Previous score

7.74

Change



Financials

5.26

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

5.74

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.69

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Halozyme Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-03-25

The current valuation score of Halozyme Therapeutics Inc is 7.16, ranking 92 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 23.92, which is 57.68% below the recent high of 37.71 and 51.44% above the recent low of 11.61.

Score

Industry at a Glance

Previous score

7.16

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 36/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-25

The current earnings forecast score of Halozyme Therapeutics Inc is 7.11, ranking 117 out of 157 in the Pharmaceuticals industry. The average price target is 77.00, with a high of 92.00 and a low of 56.00.

Score

Industry at a Glance

Previous score

7.11

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

84.500

Target Price

+34.43%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Halozyme Therapeutics Inc

HALO

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-25

The current price momentum score of Halozyme Therapeutics Inc is 6.79, ranking 85 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 69.35 and the support level at 59.31, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.58

Change

0.21

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.306

Sell

RSI(14)

35.193

Neutral

STOCH(KDJ)(9,3,3)

25.916

Buy

ATR(14)

1.781

High Vlolatility

CCI(14)

-70.279

Neutral

Williams %R

74.674

Sell

TRIX(12,20)

-0.615

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

62.968

Buy

MA10

63.513

Sell

MA20

66.015

Sell

MA50

70.835

Sell

MA100

69.496

Sell

MA200

67.020

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-25

The current institutional shareholding score of Halozyme Therapeutics Inc is 10.00, ranking 1 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 106.06%, representing a quarter-over-quarter increase of 3.42%. The largest institutional shareholder is The Vanguard, holding a total of 11.54M shares, representing 9.78% of shares outstanding, with 5.90% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

11.60M

-5.05%

BlackRock Institutional Trust Company, N.A.

11.38M

-2.79%

State Street Investment Management (US)

5.02M

-15.43%

Arrowstreet Capital, Limited Partnership

3.29M

+29.49%

Geode Capital Management, L.L.C.

2.43M

-0.05%

Snyder Capital Management, L.P.

2.73M

-19.54%

Invesco Advisers, Inc.

1.90M

+15.79%

BofA Global Research (US)

1.39M

+2.65%

Dimensional Fund Advisors, L.P.

2.08M

+3.16%

Risk Assessment

Currency: USD Updated: 2026-03-25

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Halozyme Therapeutics Inc is 8.04, ranking 30 out of 157 in the Pharmaceuticals industry. The company's beta value is 1.04. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.